Posts in tag

new listings


A new drug therapy for women with advanced ovarian cancer has been listed on the PBS as of today – which is also the first day of Ovarian Cancer Awareness …

The first and only one-tablet, once-a-day treatment for all genotypes of chronic hepatitis C infection has been recommended for PBS listing Gilead Sciences Australia has announced that the TGA has …

The Government has subsidised another $70 million round of new revolutionary medicines that will make treatments for Type 2 diabetes cheaper and more accessible and also help save the lives …

The Society of Hospital Pharmacists of Australia has declared its support for faster and improved access to vital medicines and medical devices as announced in the 2016 Federal Budget. “The …

New therapies have been PBS listed for the treatment of genotype 1 chronic hepatitis C virus. AbbVie Australia today announced that Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and …

A cancer medicine that doubles progression free survival in people with indolent Non-Hodgkin’s Lymphoma and is less toxic than previous chemotherapy regimens will be added to the Pharmaceutical Benefits Scheme …

Professor Lisa Nissen, Debbie Rigby and Chris Campbell’s fast facts on the new Hepatitis C drugs… In Australia it is estimated that more than 230,000 patients were living with chronic …

New pharmacy training to understand and dispense the new direct acting antiviral oral regimens for Hepatitis C will be available in May, but pharmacists need to learn as much as …

Now that new generation medicines for hepatitis C have been subsidised on the PBS, the Government needs to invest in raising awareness about them and the disease, stakeholders say. In …

Stakeholders have welcomed the announcement yesterday that a range of curative breakthrough hepatitis C medicines will be added to the PBS next year. Health Minister Sussan Ley announced that the …

Boehringer Ingelheim has announced the availability of the first tiotropium-based combination therapy on the PBS for the treatment of chronic obstructive pulmonary disease (COPD).

Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.